文献速递瓣膜外科

机器人主动脉瓣置换术国际多中心纵向结局

Longitudinal outcomes following international multicentre experience with robotic aortic valve replacement†.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

该研究汇总10个国际中心2020年1月至2024年7月连续接受标准化经腋下侧小切口内镜机器人辅助主动脉瓣置换术(RAVR)的300例患者,中位预测风险1.6%,随访1年。结果显示无中转胸骨切开,30天手术死亡2例(0.7%),1年随访瓣膜功能良好,认为RAVR安全有效,可作为低中危主动脉瓣疾病患者的选择。

要点

  • 300例RAVR患者无中转胸骨切开,30天手术死亡2例(0.7%)。
  • 术后再开胸清除血胸8.3%,永久起搏器植入率2.6%。
  • 1年随访平均主动脉瓣压差10 mmHg,仅1.2%有轻度以上瓣周/人工瓣反流。

核心结论

  • RAVR安全有效,在保留外科主动脉瓣置换可重复获益的同时创伤更小,并允许合并手术。
  • 对低、中危主动脉瓣疾病患者,RAVR是患者和心脏团队可重复选择的替代方案。

研究设计与样本

  • 国际多中心连续病例系列,10个中心,2020年1月至2024年7月,中央数据库随访1年。
  • 共分析300例接受标准化经腋下侧小切口内镜机器人辅助主动脉瓣置换术的患者。

主要发现

  • 中位预测风险1.6%,主动脉瓣狭窄占85.7%,近半数为二叶式主动脉瓣。
  • 生物瓣植入220例(73.3%),中位瓣膜尺寸23 mm,10%行主动脉根部扩大,17%同期行合并手术。
  • 中位主动脉阻断时间120分钟,无中转胸骨切开;中位住院5天,延长通气4.3%,肾衰竭1.7%,卒中1.0%,再开胸清除血胸8.3%。
  • 30天手术死亡2例(0.7%),全队列新永久起搏器植入率2.6%。
  • 163例完成1年临床与超声随访者平均主动脉瓣压差10 mmHg,除2例(1.2%)外均为微量或无人工瓣/瓣周反流。

临床怎么用

  • 对低、中危主动脉瓣疾病患者,RAVR可作为外科主动脉瓣置换的可重复微创替代选择。
  • RAVR可同期处理合并手术,选择时需权衡再开胸止血与起搏器植入等围术期风险。

局限性

  • 1年完整临床与超声随访仅163例,随访时间有限。
  • 为单臂多中心经验,缺乏与常规手术或其他入路的对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In an effort to maintain the technical aspects of traditional prosthetic surgical aortic valve replacement (AVR) while reducing invasiveness and facilitate options for concomitant operations, transaxillary lateral mini-thoracotomy endoscopic robotic-assisted aortic valve replacement (RAVR) has been introduced. The present data highlight the contemporary international collaborative experience. METHODS: All consecutive patients undergoing standardized RAVR across 10 international sites (1/2020-7/2024) were evaluated using a central database with 1 year follow-up. RESULTS: A total of 300 patients were analysed with a median predicted risk of 1.6% with aortic stenosis in 85.7%, nearly half with bicuspid valves. Biological prostheses were implanted in 220 (73.3%) with a median valve size 23 mm, 10% receiving aortic root enlargement, with 17% of all patients undergoing concomitant procedures. Median cross-clamp 120 min with no conversions to sternotomy. Median length of stay was 5 days, 4.3% with prolonged ventilation, 1.7% renal failure, 1.0% stroke and 8.3% required re-thoracotomy for evacuation of haemothorax. There were two 30-day operative mortalities (0.7%). The new permanent pacemaker rate for the full cohort was 2.6%. Of 163 patients with complete 1-year clinical and echocardiographic follow-up, mean aortic valve gradient was 10 mmHg and all but 2 patients (1.2%) had trace to no prosthetic or paravalvular insufficiency. CONCLUSIONS: RAVR is safe and effective, providing the reproducible benefits of surgical AVR while affording a less invasive approach that permits the opportunity for concomitant procedures. For low and intermediate risk patients with aortic valve disease, RAVR is a potential reproducible alternative for patients and heart teams.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Wei LM, Pereda D, Ramzy D, et al. Longitudinal outcomes following international multicentre experience with robotic aortic valve replacement†. Eur J Cardiothorac Surg. 2025. PMID: 40131409. doi:10.1093/ejcts/ezaf103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。